Should a weight‑based bolus of unfractionated heparin be administered in a patient with unstable angina (non‑ST‑segment elevation acute coronary syndrome)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Heparin Bolus for Unstable Angina

Yes, you must administer a weight-based bolus of unfractionated heparin for unstable angina (NSTE-ACS), followed by continuous infusion, as parenteral anticoagulation is a Class I recommendation in all current guidelines. 1

Initial Bolus Dosing

The recommended initial bolus is 60-70 IU/kg (maximum 4000-5000 IU) intravenously, followed immediately by a continuous infusion of 12-15 IU/kg/hour (maximum 1000 IU/hour). 2, 3 The 2020 ESC guidelines specify a weight-adjusted bolus during PCI of 70-100 IU/kg, or 50-70 IU/kg when combined with a GP IIb/IIIa inhibitor. 1

Rationale and Evidence Base

  • Parenteral anticoagulation is recommended for all patients with NSTE-ACS at the time of diagnosis, in addition to antiplatelet therapy, according to both ischemic and bleeding risk profiles (Class I, Level A). 1

  • Unfractionated heparin remains the standard of care for NSTE-ACS patients due to its favorable risk-benefit profile. 1

  • The combination of aspirin plus heparin shows a modest but clinically meaningful reduction in death or MI compared to aspirin alone (OR 0.74,95% CI 0.5-1.09), though this did not reach statistical significance in pooled analyses. 1, 4

  • Heparin is considered fundamental therapy when given in conjunction with antiplatelet agents (Class IA). 1

Monitoring and Target

  • Target activated partial thromboplastin time (aPTT) of 50-70 seconds (some guidelines specify 60-80 seconds). 2, 3

  • During PCI, target activated clotting time (ACT) of 250-350 seconds, or 200-250 seconds if a GP IIb/IIIa inhibitor is administered. 1

Duration of Therapy

  • Continue parenteral anticoagulation until revascularization (PCI or CABG) is performed. 2

  • For patients not undergoing an invasive approach, continue for the duration of hospitalization (maximum 8 days). 2

  • Discontinue immediately after PCI for uncomplicated cases. 1

Alternative Anticoagulants

While UFH with bolus is standard, alternatives exist:

  • Enoxaparin (LMWH) has shown superiority to UFH in two large trials (ESSENCE and TIMI-11B) and is preferred over UFH unless CABG is planned within 24 hours (Class IIa, Level A). 1

  • Fondaparinux is recommended when medical treatment is planned or logistical constraints delay PCI transfer, but requires a single UFH bolus at the time of PCI to prevent catheter thrombosis. 1, 2

  • Bivalirudin may be considered as an alternative to UFH (Class IIb, Level A). 1

Critical Pitfalls to Avoid

  • Never skip the bolus—the bolus achieves immediate therapeutic anticoagulation while the infusion takes hours to reach steady state. 2, 3

  • Avoid crossover between UFH and LMWH (Class III, Level B), as this increases bleeding risk without added benefit. 1

  • Reduce dosing with GP IIb/IIIa inhibitors—use 50-70 IU/kg bolus instead of 70-100 IU/kg to minimize bleeding. 1

  • Adjust for renal impairment—in patients with CrCl <30 mL/min, UFH is strongly preferred over LMWH due to renal accumulation and unpredictable anticoagulation with LMWH. 5

  • Excessive anticoagulation increases bleeding risk, particularly when combined with fibrinolytics or GP IIb/IIIa inhibitors. 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Unfractionated Heparin Dosing for Acute Coronary Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

European Society of Cardiology Recommendations on Anticoagulation for Unstable Angina and NSTEMI

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Anticoagulation Management in Acute Kidney Injury

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.